Pathological conditions in the central nervous system, including stroke and trauma, are often exacerbated by cerebral edema. We recently identified a nonselective cation channel, the NC Ca-ATP channel, in ischemic astrocytes that is regulated by sulfonylurea receptor 1 (SUR1), is opened by depletion of ATP and, when opened, causes cytotoxic edema. Here, we evaluated involvement of this channel in rodent models of stroke. SUR1 protein and mRNA were newly expressed in ischemic neurons, astrocytes and capillaries. Upregulation of SUR1 was linked to activation of the transcription factor Sp1 and was associated with expression of functional NC Ca-ATP but not K ATP channels. Block of SUR1 with low-dose glibenclamide reduced cerebral edema, infarct volume and mortality by 50%, with the reduction in infarct volume being associated with cortical sparing. Our findings indicate that the NC Ca-ATP channel is crucially involved in development of cerebral edema, and that targeting SUR1 may provide a new therapeutic approach to stroke.
Pathological conditions in the central nervous system, including stroke and trauma, are often exacerbated by cerebral edema. We recently identified a nonselective cation channel, the NC Ca-ATP channel, in ischemic astrocytes that is regulated by sulfonylurea receptor 1 (SUR1), is opened by depletion of ATP and, when opened, causes cytotoxic edema. Here, we evaluated involvement of this channel in rodent models of stroke. SUR1 protein and mRNA were newly expressed in ischemic neurons, astrocytes and capillaries. Upregulation of SUR1 was linked to activation of the transcription factor Sp1 and was associated with expression of functional NC Ca-ATP but not K ATP channels. Block of SUR1 with low-dose glibenclamide reduced cerebral edema, infarct volume and mortality by 50%, with the reduction in infarct volume being associated with cortical sparing. Our findings indicate that the NC Ca-ATP channel is crucially involved in development of cerebral edema, and that targeting SUR1 may provide a new therapeutic approach to stroke.
Edema complicates many conditions that affect the central nervous system (CNS), including stroke and trauma. Edema worsens neurological function and can threaten life. Swelling resulting from malignant cerebral edema after a large middle cerebral artery (MCA) stroke is responsible for the high mortality of 60-80% of the patients 1 . Molecular mechanisms of cerebral edema are poorly understood, and available treatments are nonspecific and only moderately effective 1 .
SUR1 is a regulatory subunit that associates with Kir6.x poreforming subunits to form heterooctameric K ATP channels 2 . SUR1 confers sensitivity to sulfonylurea inhibitors such as glibenclamide and to channel activators such as diazoxide. Apart from involvement with K ATP channels, SUR1 also regulates activity of a nonselective cation channel, the NC Ca-ATP channel 3 . First identified in freshly isolated (but not cultured) reactive astrocytes, this channel conducts monovalent cations, requires nanomolar concentrations of intracellular Ca 2+ for opening, and is activated by depletion of intracellular ATP 4 . Opening of NC Ca-ATP channels causes complete depolarization and cell blebbing, characteristic of cytotoxic edema. Depolarization and blebbing induced by depletion of ATP are prevented by glibenclamide, and are reproduced without depletion of ATP by diazoxide, consistent with a crucial role for NC Ca-ATP channels in cytotoxic edema 3 .
Because the NC Ca-ATP channel was first discovered in hypoxic gliotic tissues, we postulated that other causes of hypoxia, including arterial occlusion, might also be associated with channel expression. We thus studied rodent models of stroke (permanent focal cerebral ischemia) after MCA occlusion (MCAO). For most of our experiments, we used a model of massive MCA infarction associated with malignant cerebral edema (MCE) and high mortality. Alternatively, to study effects on infarct volume, we used a thromboembolic model associated with nonlethal infarctions. Here, we report that expression of NC Ca-ATP channels is upregulated after MCAO, and that block by low-dose glibenclamide results in major improvements in stroke outcome.
RESULTS

Upregulation of SUR1 in MCE model
We used immunohistochemical analysis and immunoblots to determine expression of SUR1 in three regions after ischemia: the uninvolved hemisphere, the peri-infarct region, and the core of the infarct, with the core identified by absence of perfusion (Fig. 1a) , absence of 2,3,5-triphenyltetrazolium chloride (TTC) staining 5 (Fig. 1b) and absence of glial fibrillary acidic protein (GFAP) immunolabeling 6 (data not shown).
In the core, levels of SUR1 increased significantly above background levels 2-3 h after MCAO (Fig. 1c-g ). Unlike contralateral tissues, virtually every NeuN + cell (Fig. 1d) and capillary in the core was positive for SUR1, with labeling also evident in some NeuN -cells. Levels of SUR1 remained elevated at 6 h, but declined by 8 h (Fig. 1g) , coinciding with the appearance of necrosis. At all times, SUR1 in the core far exceeded levels in contralateral regions 7, 8 (Fig. 1g) .
In TTC + peri-infarct regions, levels of SUR1 increased later than in the core, but the increase was sustained (Fig. 1g) . By 8-16 h after MCAO, SUR1 sharply demarcated core and peri-infarct regions (Fig. 1c) , and was evident in NeuN + neurons, GFAP + astrocytes (Fig. 1e) and von Willebrand factor + capillary endothelial cells (Fig. 1f) .
Immunohistochemical changes in expression of SUR1 at 8 h (Fig. 1g) were confirmed by immunoblots at 8 h (Fig. 2a,b) . Also, immunoblots of TTC + peri-infarct regions, where necrosis could not confound antibody binding, showed that levels of SUR1 increased progressively over 8 h to approximately three times higher than control levels (Fig. 2a,b) . We confirmed the specificity of the antibody used for immunohistochemistry and immunoblots in separate experiments (Fig. 2b) .
The ischemia-induced increase in SUR1 was corroborated by measurements of Abcc8 mRNA (encoding SUR1), which increased two-to threefold in the core at 3 h (Fig. 2c) . In situ hybridization showed that SUR1 transcripts were present in neurons and capillaries in the core but not in control tissues (Fig. 2d-g ). Thus, cerebral ischemia resulted in substantial transcriptional upregulation of SUR1.
Sp1 and Sp3 transcription factors
The promoter region of Abcc8 contains consensus sequences for binding Sp1, and Sp1 drives expression of SUR1 in a concentrationdependent manner 9, 10 . In the core of the infarct, nuclear labeling for Sp1 was evident at 1 h and was more prominent 3 h after MCAO, especially in large neuron-like cells (Fig. 3a,b) . Double immunolabeling showed that many Sp1 + cells also labeled for SUR1 (Fig. 3c) . In peri-infarct areas, nuclear localization of Sp1 was evident in capillaries and in other cells at 3-6 h (Fig. 3d,e) . Immunoblots of nuclear extracts showed a three-to fourfold increase in nuclear Sp1 in the core, compared to control (Fig. 3f) . Expression of Sp3, which may ultimately determine transcriptional activity of Sp1 by virtue of its inhibition of Sp1 binding, was unchanged (Fig. 3f) .
Sp1 is a key driver of SUR1 expression in vitro 9, 10 , but this association has not been validated for CNS cells in vivo. Chromatin immunoprecipitation of DNA extracted from the core 2 h after MCAO using Sp1-specific antibody showed prominent PCR products for the Sp1 binding region of the Abcc8 promoter, but not for the promoter region of Crp, which encodes C-reactive protein (Fig. 3g) and which has no consensus binding sites for Sp1. Thus, transcriptional upregulation of SUR1 in cerebral ischemia could be ascribed, at least in part, to activation of Sp1.
NC Ca-ATP channel in neurons after MCAO Although SUR1 was upregulated in cerebral ischemia, the poreforming subunits of K ATP channels, Kir6.1 or Kir6.2, were not (Fig. 2b) . Apart from its involvement in K ATP channels, SUR1 also forms the regulatory subunit of NC Ca-ATP channels 3 . As the poreforming subunit of the NC Ca-ATP channel has not been cloned, we used its biophysical properties for identification. We studied insideout patches of large neuron-like cells isolated from the core 2 h and 6 h after MCAO (Fig. 4a-d) . Using Cs + as the charge carrier to block K + channels, including K ATP , we found that neurons from the core expressed channels that: (i) conducted Cs + ; (ii) were strongly inhibited by ATP on the cytoplasmic side; (iii) required Ca 2+ on the cytoplasmic side for activity (Fig. 4b) ; and (iv) were blocked by glibenclamide (Fig. 4d) . Each of these four characteristic findings 3, 4 was replicated in three to six patches from 15 rats with MCAO. Patches from eight neurons dissociated from contralateral regions and studied in the same manner, including Cs + as the charge carrier, showed no channel activity. In neurons from the core, when we used K + as the charge carrier, we observed a glibenclamide-sensitive, Ca 2+ -dependent singlechannel conductance of 34 pS (Fig. 4c) , consistent with the NC Ca-ATP channel 4 but not K ATP channels 2 . The ability to conduct Cs + , the requirement for Ca 2+ and a single-channel conductance of 34 pS with K + unambiguously distinguish the NC Ca-ATP channel from K ATP channels. Thus, upregulation of SUR1 in cerebral ischemia was associated with expression of NC Ca-ATP but not K ATP channels.
Glibenclamide is a potent blocker of NC Ca-ATP channels (50% effective concentration (EC 50 ) ¼ 48 nM at pH 7.4, 22 1C) 3 . In neurons from the core, 50 nM glibenclamide (pH 7.4) reduced the open probability of NC Ca-ATP channels to 56.1 ± 6.5% of baseline values (Fig. 4d) . It is the un-ionized form of the weak acid, glibenclamide (pK a 6.3), however, that is responsible for channel block 11, 12 , and at Association of Sp1 and SUR1 promoter region in cerebral ischemia. (a-e) Immunofluorescence imaging for Sp1 in contralateral control region (a), in the core of the infarct 3 h after MCAO (b,c) and in the peri-infarct region 6 h after MCAO (d,e). In c, the section was double labeled for Sp1 (green) and SUR1 (red). In e, the section was also stained with the nuclear marker DAPI, with pink indicating nuclear localization of Sp1 (arrows). (f) Immunoblots of nuclear lysates and densitometric analyses of blots for Sp1 and Sp3, with Histone 3 (H3) as control, for contralateral control (CTR) and core (INF) tissues 3 h after MCAO. **P o 0.01. (g) Electrophoretic gels of PCR products for the proximal promoter regions of Abcc8 and the negative control, Crp.
Chromatin isolated from the core of the infarct 2 h after MCAO in three different animals. DNA templates were: (i) 20 mg chromatin 'immunopreciptated' using nonspecific mouse IgG as negative control (IgG); (ii) 2 mg total chromatin as positive control (Input or Inp.); or (iii) 20 mg chromatin immunopreciptated using Sp1-specific antibody (Anti-Sp1). Scale bars in a and d, 100 mm; in c, 10 mm; in e, 25 mm. pH 7.4, only 7% is un-ionized. We reasoned that the apparent potency of glibenclamide would increase at the acidic pH found in ischemic brain 13 . In the same neurons from the core, reducing the pH to 6.8 decreased the open probability with 50 nM glibenclamide to 12.0 ± 4.4% of baseline values (Fig. 4d) , consistent with block by the un-ionized form.
Glibenclamide is cytoprotective
Opening of NC Ca-ATP channels after sodium azide-induced depletion of ATP results in cytotoxic edema (oncotic cell blebbing) 3,4 , a precursor of oncotic cell death. We postulated that block of this channel by glibenclamide would protect cells from death. We tested this using astrocytes freshly isolated from the ischemic inner zone of gliotic capsules, where NC Ca-ATP channels are expressed 3, 4 . Exposure of the cells to sodium azide resulted in a high incidence of oncotic death, as indicated by nuclear labeling with propidium iodide (Fig. 4e,g ). Apoptotic death, as measured by annexin V labeling, was not prominent (Fig. 4f,g ). Pretreatment with glibenclamide before exposure to sodium azide resulted in a significant reduction in cell death (P o 0.01; Fig. 4e,g) , showing cytoprotection by glibenclamide in the context of depletion of ATP after ischemia.
Glibenclamide treatment in MCE model
To determine the role of NC Ca-ATP channels in cerebral ischemia, we studied the effects of glibenclamide, the highly selective inhibitor of SUR1 (ref. [14] [15] [16] . We used constant infusion of a low dose of drug to achieve sustained occupancy of only high-affinity receptors. In a large group of male and female rats with MCAO (MCE model), treatment with glibenclamide resulted in a marked reduction in mortality compared to treatment with saline, from 65% to 24% (P o 0.002; Fig. 5a ). Delayed deaths were not observed with glibenclamide, indicating that the effect was durable.
As glibenclamide prevents cytotoxic edema 3,4 , we postulated that the beneficial effect on mortality might be the result of a reduction in cerebral edema. We studied the effect of glibenclamide on cerebral edema 8 h after MCAO, a time that preceded death of any rat in the mortality study. In the first of two experiments, we compared water content in the involved and uninvolved hemispheres. For the control hemisphere, water was 77.9 ± 0.2% of tissue wet weight. For the involved hemisphere, water increased by 3.4%, to 81.3 ± 0.5% for the saline-treated group, whereas it increased by only 2.0%, to 79.9 ± 0.3%, for the glibenclamide-treated group (P o 0.05), consistent with an important role for SUR1-regulated NC Ca-ATP channels in formation of edema.
After stroke, a cerebral hemisphere includes normal, infarcted and ischemic peri-infarct tissues, each of which contains different amounts of water. To characterize the location of edema at 8 h, we measured water content after dividing tissues into viable TTC + and nonviable TTC -portions. Water in the uninvolved hemisphere was 78.0 ± 0.1% (Fig. 5b) , similar to the previous value of 77.9 ± 0.2%, indicating that TTC processing had not altered water content. For the involved hemisphere, water in TTC + tissues increased by 5.4% or 5.9%, to 83.4 ± 1.1% or 83.6 ± 0.9%, for groups treated with either saline alone or with vehicle, respectively, whereas it increased by only 2.3%, to 80.5 ± 0.3% (P o 0.05), for the glibenclamide-treated group (Fig. 5b) . In contrast, values for water in TTC -tissues, 78.7 ± 1.0%, 78.4 ± 0.8% and 78.6 ± 0.4% with saline, vehicle and glibenclamide, respectively, were only slightly higher (P ¼ 0.97) than values for the uninvolved hemisphere (78.0%), reflecting a need for blood flow to form edema (Fig. 5b) 1 . Together, these data indicate that excess water originated predominantly from peri-infarct regions, and that glibenclamide was highly effective in reducing it. The previous data indicate that protective effects of glibenclamide could not be attributed to dimethylsulfoxide in the vehicle. As additional controls, we considered potential effects of glibenclamide on serum glucose and on blood pressure. When measured in rats from the edema studies, serum glucose at 8 h was decreased by glibenclamide (122 ± 4 versus 93 ± 3 mg/dl; P o 0.05; 11 rats/group). The reduction was significant, confirming that serum levels of glibenclamide were sufficient to affect pancreatic SUR1, but such levels of glucose are not associated with altered outcome in ischemia 17, 18 . Systolic blood pressure measured at 8 h was not affected by glibenclamide (120 ± 7 versus 109 ± 6 mmHg; P ¼ 0.26; 11 rats/group).
Glibenclamide treatment in thromboembolic model
Given the marked effects on mortality and edema, we sought to determine the effect of glibenclamide on infarct volume. This was not feasible with the MCE model because of high early mortality. We therefore utilized a nonlethal thromboembolic model to assess infarct volume at 2 and 7 d after MCAO. At 2 d, glibenclamide treatment resulted in a highly significant reduction in infarct volume, compared to controls treated with saline (35.5 ± 4.4% versus 16.7 ± 2.2%; P o 0.01; Fig. 5c-e) . We made a similar observation at 7 d (15.2 ± 1.2%; P o 0.01), again indicating that effects of treatment were durable.
All rats, regardless of treatment group, suffered infarctions involving the basal ganglia, which are supplied by terminal arterioles.
Reduced infarct volumes in the glibenclamide-treated groups, however, were often associated with marked sparing of the cerebral cortex (Fig. 5c,d) , a phenomenon previously reported with decompressive craniectomy 19 .
We hypothesized that cortical sparing with glibenclamide might reflect improved leptomeningeal collateral blood flow, which could result from reduced cerebral edema, but not from direct vasodilation, because normally glibenclamide is vasoconstrictive as a result of block of K ATP channels 20, 21 . Using the same thromboembolic model, we obtained measurements of relative cerebral blood flow for somatosensory cortex supplied by the MCA. Laser Doppler flowmetry showed values in the involved hemisphere that were significantly reduced 1 h after MCAO in both saline-and glibenclamide-treated groups (Fig. 5f ). Flow recovered completely by 48 h, however, in glibenclamide-but not saline-treated rats (Fig. 5f) , consistent with the cortical sparing observed.
Tissue distribution of glibenclamide in MCE model
Low-dose glibenclamide was unexpectedly effective in reducing mortality, cerebral edema and infarct volume, yet had only a small effect on serum glucose. We thus sought to confirm that glibenclamide was reaching targeted areas of cerebral ischemia.
We used the fluorescent derivative, BODIPY-glibenclamide, to examine drug distribution 8 h after MCAO. Administration of the labeled compound at the same rate and molar concentration as the parent compound (cumulative dose, 1.2 nmol in 8 h) yielded no labeling in the uninvolved hemisphere (Fig. 6a,b) , consistent with exclusion by normal blood-brain barrier, and none in the core of the infarct (data not shown), consistent with absence of perfusion.
There was weak labeling in pancreatic islets of Langerhans, but prominent labeling in peri-infarct regions (Fig. 6a) , with labeling of large neuron-like cells and microvessels (Fig. 6a) , including capillaries ( Fig. 6c) , that showed expression of SUR1 (Fig. 6d) . Labeling in periinfarct tissues reflected not only an increase in SUR1 glibenclamidebinding sites, which show femtomolar binding affinity for glibenclamide 22, 23 , but also indicated that normal permeability barriers no longer excluded the drug. Selective distribution of drug to peri-infarct tissues may have been facilitated by breakdown of the blood-brain barrier, but was undoubtedly driven by an increase in lipid solubility of the weak acid, glibenclamide, as a result of the low pH of ischemic peri-infarct tissues 13 .
DISCUSSION
Here, we show that SUR1 is transcriptionally upregulated in focal cerebral ischemia, initially in the core, and later in peri-infarct regions, with involvement of neurons, astrocytes and capillary endothelial cells. Ischemia-induced upregulation of SUR1 was attributable, at least in part, to activation of the transcription factor Sp1. Sp1 has previously been shown to be a crucial driver of SUR1 expression 9, 10 , and activation of Sp1 has previously been associated with ischemiahypoxia 24, 25 ; but our data show Sp1 activation in cerebral ischemia and link this with expression of SUR1. SUR1 forms the regulatory subunit of both K ATP and NC Ca-ATP channels. Based on immunoblots for Kir6.1 or Kir6.2 and on electrophysiological experiments, we found that K ATP channels were not upregulated, whereas NC Ca-ATP channels were. The NC Ca-ATP channel was previously characterized in astrocytes 3, 4 , and here we identified it in neurons after onset of ischemia. The key biophysical properties that distinguish NC Ca-ATP from K ATP channels include: (i) nonselective monovalent cation conductivity, including for Cs + , which is a blocker of K ATP channels; (ii) a requirement for intracellular Ca 2+ , which does not exist for K ATP channels; and (iii) a single-channel conductance of 34 pS with K + , which is 50% of that for K ATP channels 2 . These three properties are probably attributable to the pore-forming subunits, as the SUR1 regulatory subunits of the two channels are functionally indistinguishable.
Cerebral edema is a complex pathophysiological process that causes brain swelling, neurological dysfunction and may ultimately lead to brain herniation and death 1, 26 . Cerebral edema initially results from formation of 'cytotoxic' (cellular) edema, which is inextricably bound to cell death. Cytotoxic edema, which forms early in the core of the infarct, depletes the extracellular space of Na + , creating a concentration gradient for Na + between infarct and peri-infarct regions. This gradient later drives passive transcapillary flux of Na + that is integral to formation of 'ionic' edema in peri-infarct regions 27 . In both cytotoxic and ionic edema, movements of Na + are accompanied by secondary movements of Cl -and H 2 O, driven by electrical and osmotic forces. The molecular entity, channel or otherwise, that allows passive movement of Na + down its electrochemical gradient has not been previously identified. We hypothesize that newly expressed NC Ca-ATP channels constitute this heretofore unidentified pathway for Na + flux required for formation of edema. Block of this channel by glibenclamide is highly effective in preventing Na + influx, cell depolarization and cell blebbing, all hallmarks of cytotoxic edema, in isolated cells in vitro that express the NC Ca-ATP channel 3, 4 . Here, we show in the same cells that glibenclamide also protects from cell death, the ultimate consequence of cytotoxic edema. Moreover, we show that glibenclamide in vivo is highly effective in reducing accumulation of excess brain water, the hallmark of ionic edema, in peri-infarct tissues that express the NC Ca-ATP channel. It seems that, in vivo, early upregulation of NC Ca-ATP channels in neurons in the core is associated with formation of cytotoxic edema, whereas later upregulation of NC Ca-ATP channels in capillaries in peri-infarct regions is associated with formation of ionic edema.
Numerous neuroprotective strategies assessed over the last decade have failed in human trials, in part as a result of dose-limiting side effects. In contrast, glibenclamide has been used safely in humans for several decades for treatment of type 2 diabetes, with no untoward side effects except hypoglycemia. We found that constant infusion of low-dose glibenclamide caused only slight reduction of serum glucose, but was highly effective in reducing cerebral edema, infarct volume and mortality in rodent models of stroke. Three features combine to maximize beneficial effects while minimizing potential side effects of glibenclamide: (i) its molecular target resides within the lipid plasmalemmal membrane 11, 12 ; (ii) as a weak acid, its lipophilicity, which determines its ability to reach its target, increases in acidic medium; and (iii) targeted ischemic tissues are acidic 13 . Thus, the safety of glibenclamide, as borne out by decades of use in humans, and the efficacy of glibenclamide, as shown here, indicate that glibenclamide may be particularly attractive for translational use in human stroke.
The neuroprotection afforded by glibenclamide, which we observed at both the cellular and organ levels, predicts that glibenclamide would also improve functional neurological outcome in stroke. Moreover, the time required for transcriptional upregulation of NC Ca-ATP channels after onset of ischemia predicts that glibenclamide would have a favorable therapeutic time window. Overall, our data indicate that molecular therapies directed at the SUR1-regulated NC Ca-ATP channel may provide new avenues of treatment for CNS injuries associated with ischemia. 
